Biotech Venture Funding Tracker 2026

Public clinical-stage immunology company developing zumilokibart, an anti-IL-13 antibody for moderate-to-severe atopic dermatitis and broader inflammatory indications. Financing provides up to US$800M of synthetic royalty capital and up to US$500M of senior debt to support Phase 3 development and potential commercialization.

Longevity biotech developing therapies intended to add healthy years of life, with programs spanning autophagy, plasma-inspired therapeutics, and cellular reprogramming. The initial close funds the next phase of clinical and platform development at a disclosed US$1.8B pre-money valuation.

Clinical-stage biotech launched to develop therapies for idiopathic pulmonary fibrosis and other fibrotic diseases. Proceeds support ORJ-001, a first-in-class therapeutic in-licensed from NIBEC, with IND clearance received and a Phase 2 IPF trial planned in 2026.

San Diego-based I&I biotech launched by former Roivant executives to build an immunology and inflammation pipeline around in-licensed drug assets. Series A proceeds support pipeline build-out and development of its initial clinical and preclinical programs.

Radiopharmaceutical company developing a global pipeline of radioligand therapies and related manufacturing capabilities. Financing includes approximately US$110M of Series D equity and US$40M of debt to advance multiple clinical-stage assets and expand manufacturing infrastructure.

Clinical-stage biotech developing oral therapies targeting regulatory cell death and inflammation. Proceeds fund a Phase 2b trial of AC-101, a selective RIPK2 inhibitor, in ulcerative colitis and support additional I&I pipeline candidates.

RNA-based in vivo CAR therapies designed to reprogram immune cells inside the body. Proceeds advance its in vivo CAR pipeline across autoimmune disease and oncology, supporting clinical development and platform expansion.

Clinical-stage molecular glue degrader company developing GlueXplorer-enabled small molecules. Proceeds support continued clinical development of DEG6498, advancement of immunology programs toward development-candidate stage, and expansion of its molecular glue degrader discovery platform.

AI-first drug design and development company spun out of Google DeepMind. Proceeds support scaling of its AI drug-design engine, continued team expansion, and advancement of its internal and partnered drug candidate pipeline.

Clinical-stage biopharma developing ANG003, an oral enzyme replacement therapy for exocrine pancreatic insufficiency including EPI due to cystic fibrosis, pancreatic cancer, and related disorders. Financing supports Phase 2b and Phase 3 development and manufacturing scale-up.

Microbiome therapeutics company developing live biotherapeutic approaches for cancer. Proceeds advance its lead immuno-oncology drug candidate, designed to improve the efficacy of immunotherapy in solid tumours, while supporting platform development and clinical translation.

Clinical-stage oncology biotech developing inobrodib, a first-in-class oral p300/CBP inhibitor, for multiple myeloma. Financing supports registration-enabling trials, with the company also positioning around potential IPO optionality.

UK biotech developing differentiated multispecific immune cell engager antibodies designed to activate pan-gamma delta T cells. Proceeds advance CYT X300 for EGFR-positive cancers toward clinical proof-of-concept.

Clinical-stage immunology biotech developing long-acting antibody therapies for serious respiratory and dermatological diseases. Proceeds advance anti-TSLP antibody WIN378 toward Phase 3 and support WIN027, a long-acting TSLP x IL-13 bispecific.

Gene therapy company engineering AAV capsids and delivery approaches to expand gene therapy into larger patient populations. Proceeds advance LTS-201 for Huntington's disease toward IND submission and LTS-101 for CLN2 disease toward initial clinical data.

China-based biotech developing in vivo CAR-T therapies. Proceeds advance lead candidate GT801, currently in Phase 1 for relapsed or refractory CD19-positive B-cell malignancies, support regulatory preparations, and expand the in vivo CAR-T platform.

Belgium-based immunology biotech, formerly Onco3R Therapeutics, advancing COL-5671, an oral SIK3 inhibitor licensed from Galapagos. Proceeds support development across autoimmune indications including psoriasis and ulcerative colitis.

Neuroscience company launched by former Sage Therapeutics executives with four Phase 2-stage assets licensed from Eisai and Hansoh. Pipeline covers major depressive disorder, generalised anxiety disorder, Alzheimer's disease psychosis, and Parkinson's disease psychosis.

Clinical-stage biotech developing optogenetic gene therapies for retinal degenerative diseases. Proceeds advance vision restoration pipeline including clinical-stage programs for retinitis pigmentosa and Stargardt disease.

Flagship-founded biotech building a platform for redosable modified DNA medicines designed to introduce new genetic material into cells without the durability and repeat-dosing constraints of current genetic medicine approaches.

Clinical-stage biotech developing small-molecule modulators of RNA-modifying enzymes for cancer. Proceeds support the Phase 2 sarcoma study of METTL3 inhibitor STC-15 and broader expansion into additional oncology settings.

Precision immunology company launched with five Bristol Myers Squibb-licensed programs for autoimmune and inflammatory diseases. Lead asset afimetoran, an oral lupus candidate, expected to complete Phase 2 in 2H 2026.

Biotech developing highly targeted covalent small-molecule medicines. Proceeds advance selective AKT1 inhibitor programs including TER-2013 in oncology and support pipeline expansion into hereditary haemorrhagic telangiectasia.

Clinical-stage biotech developing molecular glue degraders against historically undruggable targets. Financing supports the ongoing Phase 1/2 trial of NEO-811 in locally advanced or metastatic non-resectable clear cell renal cell carcinoma.

Biotechnology company developing extrahepatic RNA-targeting therapeutics and proprietary delivery technologies designed to move RNA medicines beyond the liver. Proceeds advance delivery platform and accelerate multiple pipeline programs into clinical development.

Global clinical-stage biotechnology company developing cancer immunotherapies, with a focus on solid-tumor CAR-T and in vivo CAR-T technologies. Proceeds support development of Ori-C101, a GPC3-targeted autologous CAR-T for advanced hepatocellular carcinoma.

Precision oncology company developing bispecific antibody-drug conjugates designed to improve tumour selectivity and widen the therapeutic window in solid tumours. Proceeds advance lead programs into clinical development and expand the broader ADC pipeline.

Clinical-stage biotech developing cellular rejuvenation therapies based on partial epigenetic reprogramming. Financing supports the Phase 1 clinical trial of ER-100 in optic neuropathies and continued development of the broader Partial Epigenetic Reprogramming platform.

Precision oncology company emerging from stealth with its Pointillist™ platform, designed to drive targeted delivery of potent anti-cancer payloads while widening the therapeutic window. Proceeds advance lead asset STP-100 into early clinical studies.

Beijing-based macrocyclic peptide drug discovery company using its AI-enabled Synova™ platform to build a diversified pipeline targeting oncology, autoimmune, metabolic, and rare diseases. Proceeds advance the Synova platform toward clinical-stage readiness and accelerate multiple lead programs.

Biotech developing oral small-molecule cardiometabolic therapies, led by an oral GLP-1 receptor agonist the company says has best-in-class potential. Proceeds advance the lead oral obesity program and other cardiometabolic assets into clinical development.

Spanish biotech developing ADCs that target the tumour microenvironment, with a focus on cancer-associated fibroblasts. Proceeds support clinical development of OMTX705 and advance OMTX105 and additional Quantum ADC programs into clinical trials.

Biotech developing a new generation of oral peptide medicines designed to combine biologic-level efficacy with the convenience of oral dosing. Proceeds support lead programs through clinical proof of concept in immunology and cardiometabolic diseases.

Clinical-stage neuroscience company developing novel therapies for psychiatric and neurological disorders. Lead asset blixeprodil (GM-1020), an oral NMDA receptor antagonist for major depressive disorder, expected to enter late-stage development in 2026.

UK biotech developing next-generation antibody therapy for ATTR amyloidosis. Proceeds take its lead antibody asset through clinical proof of concept in ATTR cardiomyopathy, with broader potential across additional amyloidosis indications.

AI-native biotech building next-generation antibody and biologics programs. Financing scales R&D platform, expands teams, and advances pipeline including HXN-1001, a half-life-extended anti-TL1A antibody ready for Phase 2 development.

Oncology company developing TCR-mimetic antibody therapies. Proceeds support completion of the Phase 1 trial for CBX-250 in myeloid malignancies and advance additional T-Bolt immunotherapies including CBX-663.

Clinical-stage biotech focused on kidney disease. Launch financing supports global development of AP306, a pan phosphate transporter inhibitor licensed from Alebund, with a Phase 2b study in hyperphosphataemia planned for later in 2026.

Clinical-stage biotech advancing oral therapies for movement disorders. Extension funds Phase 2 development of VIM0423 in isolated dystonia and Parkinson's disease, with topline data from both studies expected in 1H 2027.

Clinical-stage biotech developing PRO-203, a potential best-in-class CD20xCD3 T-cell engager for severe autoimmune disease. Financing supports systemic sclerosis development and expansion into additional B-cell-driven autoimmune indications.

Biopharma focused on chronic metabolic diseases. Lead asset zovaglutide (ZT002) is a monthly GLP-1 peptide in Phase 3 for weight loss in China, alongside an oral peptide obesity program and a GLP-1/FGF21 dual agonist pipeline.

Precision cardiology company spun out in connection with Novartis' acquisition of Avidity, developing targeted RNA medicines for rare genetic cardiomyopathies. Lead programs ATR-1072 and ATR-1086 target PRKAG2 syndrome and PLN cardiomyopathy respectively.

Formerly GenEdit, BreezeBio is building precise non-viral genetic medicines using its NanoGalaxy platform. Lead program BRZ-101 is designed to restore immune tolerance in type 1 diabetes.

Headache-focused biotech advancing next-generation anti-PACAP therapies. Lead asset SLTE-1009, licensed from DartsBio, is a potentially best-in-class anti-PACAP monoclonal antibody on track to enter Phase 1 in mid-2026.

Clinical-stage company focused on chronic lung disease. Proceeds support vapendavir, a first-in-class antiviral targeting rhinovirus — the leading cause of respiratory exacerbations in COPD — with initiation of the Phase 2b CARDINAL study planned for Q2 2026.

Neurodegeneration company advancing potential best-in-class therapies initially focused on Alzheimer's disease. Lead program KRSA-028 is designed to cross the blood-brain barrier via transferrin receptor binding to enable amyloid-targeted therapy in the CNS.

Advanced clinical-stage biotech focused on prevention and treatment of Bordetella pertussis. Lead candidate BPZE1 is a live attenuated intranasal pertussis vaccine; proceeds support Phase 3 development with a pivotal human challenge trial expected to begin in 2026.

Computationally driven drug discovery company using advanced modelling and high-performance computing to design and optimise oral small-molecule therapeutics. Proceeds support clinical development of a best-in-class oral STAT6 inhibitor and an oral IL-17 inhibitor.

Biotech developing RNA medicines for CNS diseases using proprietary "brain shuttle" technology to improve delivery of RNAi therapeutics across the blood-brain barrier. Proceeds support its antibody-oligo conjugate (AOC) platform as it progresses toward the clinic.

South Korea-based biotech building an AI-driven protein design platform focused on de novo antibody design. Proceeds support platform R&D, pipeline development, and global expansion.

Biotech developing disease-modifying, tunable, exosome-based regenerative therapies. Proceeds advance clinical development while scaling global manufacturing and expanding operations across the U.S., Japan, and the Middle East.

Clinical-stage biotech developing biologics aimed at improving musculoskeletal health. Proceeds support clinical development of AGA2118, AGA2115, AGA111, and broader pipeline.

Clinical-stage biotech developing multifunctional multispecific antibodies across oncology and I&I. Lead program ARC101 is a bispecific T-cell engager (CLDN6) in Phase 1; proceeds accelerate I&I portfolio and advance additional oncology programs into clinic.

Oncology company developing disruptive therapeutic modalities for solid tumors. Platform spans small molecules, next-gen ADC payloads, and molecular glues.

Commercial biotech focused on rejuvenating vision in the ageing eye. Financing supports commercialisation and launch of YUVEZZI (carbachol + brimonidine) for presbyopia.

Clinical-stage biotech developing genetic medicines to restore, treat, and prevent hearing loss. Proceeds support SENS-601 (GJB2 gene therapy) advancement toward the clinic and continued development of SENS-501.

Clinical-stage biotech developing precision immunoregulatory medicines based on tissue Treg biology. Proceeds support continued development of TRB-061 (TNFR2 agonist) in atopic dermatitis and advancement of preclinical programs TRB-071/TRB-081 toward the clinic.

Clinical-stage cardiometabolic biotech advancing CX11, an oral small-molecule GLP-1 receptor agonist. Proceeds support ongoing U.S. Phase 2 obesity study, planned global Phase 2 in T2D, and Phase 3 preparations.

Builds a portfolio by acquiring underdeveloped rare disease assets and using AI across development and commercialisation to shorten timelines for underserved patient populations.

Developing off-the-shelf therapeutic cancer vaccines targeting shared HERV-derived tumour antigens. Lead candidate ErVac01 is designed for "cold" tumours (e.g., triple-negative breast cancer, ovarian) with funding supporting first-in-human clinical development.

Clinical-stage precision cancer vaccine company advancing ITOP1 to prevent recurrence in oesophageal cancer, enabled by its antigen discovery platform.

Uses synthetic biology to uncover new footholds on hard targets for small-molecule drugging. Lead program targets mutants driving Noonan syndrome.

Clinical-stage neuropsychiatry company advancing Deraphan into Phase 2 for agitation associated with Alzheimer's disease.

Developing CLD-423, a first-in-class bispecific targeting IL-23p19 and TL1A for IBD and other inflammatory diseases. Phase 1 first subjects dosed at launch.

AI-native drug discovery company (rebranded from VantAI) building a data and ML stack for proximity-based medicines that modulate protein–protein interactions (molecular glues / PROTAC-superset).

Oncology biotech developing logic-gated "masked" T-cell engagers. Lead VIB305 targets EGFR+ solid tumours, designed as a prodrug activation concept.

Liver-focused cell therapy platform enabling scalable, functional human hepatocytes for multiple applications including bioartificial liver support and liver cell transplantation concepts.

AI-enabled regenerative biologics company advancing JUV-161, a muscle-regenerating biologic in Phase 1 for myopathic muscle degeneration.

Developing frevecitinib, an inhaled therapy for severe inflammatory respiratory disease, positioned to help non-eosinophilic asthma patients who lack good options.

Human cell programming company using opti-ox™ to produce consistent ioCells™ for drug discovery and toxicology, supporting NAMs and AI dataset generation.

Developing allogeneic umbilical cord blood-derived MSC therapies for inflammation-driven degenerative disease. Funds support Phase III planning for knee osteoarthritis and cartilage defects.

Developing AN01 (HSK39004), an inhaled dual PDE3/4 inhibitor in Phase 2 for COPD, in-licensed ex-China from Haisco.

Late-stage high-precision allogeneic T-cell therapy company preparing for potential commercialisation of Orca-T ahead of an April 2026 PDUFA date.

Uses the Helicon™ peptide platform to drug historically undruggable targets in cancer. Financing supports FOG-001 (zolucatetide) clinical development across a broad range of tumours.

Obesity and metabolic company advancing ALV-100 (bifunctional GIPR antagonist / GLP-1R agonist) plus an amylin-focused pipeline aimed at durable weight management and maintenance.

Developing "clustering antibodies" to correct dysregulated receptor signalling in severe genetic diseases. Lead DIAG723 targets hereditary haemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH).

Builds EpiTAC: modular bispecific antibody degraders targeting extracellular membrane and soluble proteins. Lead EPI-326 is an EGFR degrader headed to first-in-human.

Ocular gene therapy company advancing laru-zova for X-linked retinitis pigmentosa (XLRP) and building additional retina pipeline programs.

Clinical-stage fibrosis company developing first-in-class therapies to halt fibrosis. Advancing MTX-474 (EphrinB2 antagonist) in Phase 2a systemic sclerosis and MTX-439 (SMOC2 antagonist) toward Phase 1 for CKD-associated fibrosis.

Developing taplucainium (dry powder inhalation), a locally delivered charged sodium channel blocker designed to selectively silence activated airway nociceptors with minimal systemic exposure. Phase 2b readout expected mid-2026.

Drug discovery company using cell stress sensing (imaging + automation + AI) to build first-in-class programs. Proceeds push oncology assets including AML toward IND and clinic.

Developing photoimmunotherapy via the Alluminox® platform — a drug conjugate plus targeted light activation using a device — to kill tumour cells locally.

Clinical-stage immunology company developing a next-gen IgE depleter (PHB-050) aimed at food allergy and other atopic diseases. Phase 1 underway.

Cardiovascular prevention company advancing COR-1004 (PCSK9 siRNA) alongside a broader prediction and prevention approach to reduce ASCVD risk.